Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Cancer Prev Res (Phila). 2017 Sep 13;10(11):635–640. doi: 10.1158/1940-6207.CAPR-17-0177

Table 4.

Effect of selenium treatment and tumor recurrence on risk for gene methylation in sputum and plasma

Se Treatment1 Recurrence OR (95% CI)2 P value OR (95% CI)2 P value
(Sputum) (Plasma)
Yes Yes 0.86 (0.73–1.03) 0.11 1.03 (0.78–1.34) 0.85
Yes No
No Yes 1.43 (1.16–1.77) 0.00086 1.15 (0.75–1.34) 0.51
No No
Yes No 1.12 (0.98–1.29) 0.10 0.81 (0.65–1.01) 0.06
No No
1

A highly significant interaction was observed between selenium treatment, and tumor recurrence when assessing risk for methylation (p < 0.001).

2

Adjusted for age, sex, time between tumor resection and patient randomization, and sputum collection up to 4 years.